| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Company anticipates initial human trials to focus on AML upon IND clearance
SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces presentation of a poster on its lead compound CER-1236 at the Global Cell & Gene Therapy Summit 2024. The conference is being held July 8-10 in Boston.
The poster, titled, "Aberrant Expression of TIM-4-L is a Common Feature of AML and Potential Target for Engineered T Cell Therapy" presents data showing that TIM-4-L is prevalent on multiple acute myeloid leukemia (AML) subsets, but not present in healthy tissue. The study continues that CER-1236, CERo's lead compound, showed potent in vitro and in vivo cytotoxicity against TP53 mutant AML. Further, a full-scale toxicity study revealed that CER-1236 T cells engraft in lymphoid tissues, but do not cause any in-life observations, clinical pathology, or histopathological evaluations. This indicates that CER-1236 is not associated with any adverse toxicities against healthy tissue, even at high doses. The poster, which is being presented on July 8, 2024, can be accessed here.
Posted In: CERO
